Tests ENV-294 for moderate-to-severe atopic dermatitis in adults
Tests ENV-294 or a placebo in adults with moderate-to-severe atopic dermatitis.
Plain-language title generated from the registry record
Registry title: Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
Key facts
- Where
- Arlington, Atlanta, Auburn Hills, Bay City, Beverly Hills, Birmingham, Camp Hill, Canton, Chicago, Clarksville, Clinton Township, Fort Lauderdale, Fremont, Hot Springs, Houston, Las Vegas, Louisville, Mayfield Heights, Miami, Miramar, New Albany, New York, Norfolk, San Antonio, San Diego, Santa Monica, Warren, West Hills, West Lafayette, and Wilmington, United StatesSee the 30 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07298395, who can take part
Where in United States
- ArlingtonArlington, United StatesTaking people
- AtlantaAtlanta, United StatesTaking people
- Auburn HillsAuburn Hills, United StatesTaking people
- Bay CityBay City, United StatesTaking people
- Beverly HillsBeverly Hills, United StatesTaking people
- BirminghamBirmingham, United StatesTaking people
- Camp HillCamp Hill, United StatesTaking people
- CantonCanton, United StatesTaking people
- ChicagoChicago, United StatesTaking people
- ClarksvilleClarksville, United StatesTaking people
- Clinton TownshipClinton Township, United StatesTaking people
- Fort LauderdaleFort Lauderdale, United StatesTaking people
- FremontFremont, United StatesTaking people
- Hot SpringsHot Springs, United StatesTaking people
- HoustonHouston, United StatesTaking people
- Las VegasLas Vegas, United StatesTaking people
- LouisvilleLouisville, United StatesTaking people
- Mayfield HeightsMayfield Heights, United StatesTaking people
- MiamiMiami, United StatesTaking people
- MiramarMiramar, United StatesTaking people
- New AlbanyNew Albany, United StatesTaking people
- New YorkNew York, United StatesTaking people
- NorfolkNorfolk, United StatesTaking people
- San AntonioSan Antonio, United StatesTaking people
- San DiegoSan Diego, United StatesTaking people
- Santa MonicaSanta Monica, United StatesTaking people
- WarrenWarren, United StatesTaking people
- West HillsWest Hills, United StatesTaking people
- West LafayetteWest Lafayette, United StatesTaking people
- WilmingtonWilmington, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Enveda Therapeutics
- Trial code
- NCT07298395
- Record updated
- 25 September 2026
- Original description
The goal of this clinical trial is to learn about the safety and effectiveness of ENV-294 in adults with moderate to severe atopic dermatitis.Read full original descriptionShow less
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 12-Week Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ENV-294 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
The goal of this clinical trial is to learn about the safety and effectiveness of ENV-294 in adults with moderate to severe atopic dermatitis.
The main questions it will answer are:
* Is there an impact on the severity and area of atopic dermatitis when participants take ENV-294 * What medical problems do participants have when taking ENV-294
Participants will:
* Take drug ENV-294 or a placebo once every day for 12 weeks * Visit the clinic every 2 to 4 weeks for checkups and tests * Keep a diary of their symptoms and when they took their study drug * Return to the clinic for the final study visit at approximately week 16
Inclusion: Have chronic atopic dermatitis that was diagnosed at least 12 months prior to the first study visit; Have moderate-to-severe AD at screening and baseline as defined by the following criteria:; A vIGA score of 3 (moderate) or 4 (severe); EASI score of ≥16; BSA ≥10%; PP-NRS score of ≥4; Have had either a poor response or intolerance to topical treatments for atopic dermatitis (such as corticosteroids) within the past 6 months; Use a bland moisturizer at least daily.
Exclusion: Current or recurrent medical conditions that could affect the study drug or study assessments; Any illness that could impact participant safety or active infections; Ongoing skin condition or large tattoos that would interfere with clinical assessment; Clinically significant skin infection requiring treatment; Clinically significant abnormal laboratory assessments at screening.